Wells Fargo & Company Evoke Pharma Inc Call Options Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding EVOK
# of Institutions
16Shares Held
3.16MCall Options Held
0Put Options Held
0-
Aigh Capital Management LLC Baltimore, MD847KShares$397,8850.21% of portfolio
-
Bleichroeder LP New York, NY825KShares$387,7500.16% of portfolio
-
Altium Capital Management LP New York, NY725KShares$340,7220.25% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT675KShares$317,2500.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.9KShares$14,0290.0% of portfolio
About Evoke Pharma Inc
- Ticker EVOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 3,343,070
- Market Cap $1.57M
- Description
- Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabeti...